GlassScriptPhysician profile
Azmina A Patel
NPI 1518256544
$2,052.49
in general payments reported to CMS, 2019-2025
34 companies · $468 in 2025
The $468 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $139 · 2021: $77.07 · 2022: $189 · 2023: $391 · 2024: $483 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,115 · Education: $129 · Long Term Medical Supply Or Device Loan: $99.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,114.50 |
| Education | $128.80 |
| Long Term Medical Supply Or Device Loan | $99.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $309.52 | 2019-2025 | |
| Incyte Corporation | $203.36 | 2020-2024 | Jakafi, Pemazyre, Monjuvi |
| Pfizer INC. | $168.38 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $138.74 | 2019-2025 | Keytruda, Keytruda Qlex |
| Abbvie INC. | $113.59 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $98.53 | 2019-2025 | Opdivo |
| Sanofi-Aventis U.S. LLC | $96.00 | 2024 | |
| Celgene Corporation | $92.15 | 2019-2025 | Pomalyst, Reblozyl |
| Daiichi Sankyo INC. | $72.24 | 2020-2023 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $55.40 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $53.23 | 2019-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $51.24 | 2023-2025 | Fruzaqla, Alunbrig |
| Sobi, INC | $45.19 | 2024 | |
| Gilead Sciences, INC. | $44.44 | 2021-2025 | Trodelvy |
| Blueprint Medicines Corporation | $43.38 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $40.36 | 2025 | Talvey, Tecvayli |
| Stemline Therapeutics INC. | $33.81 | 2024-2025 | Orserdu |
| Medtronic, INC. | $32.38 | 2024 | Osteocool Rf Ablation System |
| Genzyme Corporation | $31.45 | 2019-2024 | |
| Beigene USA, INC. | $31.43 | 2024 | Brukinsa |
| Emd Serono, INC. | $28.17 | 2019-2020 | |
| Geron Corporation | $27.25 | 2025 | Rytelo |
| Array Biopharma INC | $25.49 | 2025 | Mektovi, Braftovi, Lorbrena |
| Eisai INC. | $25.34 | 2025 | |
| Acrotech Biopharma INC. | $23.94 | 2021-2022 | |
| Cti Biopharma Corp. | $23.79 | 2022 | |
| Amgen INC. | $23.35 | 2023 | Lumakras |
| Alexion Pharmaceuticals, INC. | $21.25 | 2025 | Ultomiris |
| Tempus Ai, INC | $20.12 | 2024 | |
| Aveo Pharmaceuticals, INC. | $18.54 | 2025 | |
| Boston Scientific Corporation | $17.62 | 2025 | Varithena Administration Pack |
| Pharmacyclics LLC, An Abbvie Company | $15.88 | 2020 | |
| Astellas Pharma US INC | $14.24 | 2019 | |
| Tersera Therapeutics LLC | $12.69 | 2023 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azmina Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.